Abstract 149P
Background
RAS mutations have been reported to be associated with the worst overall survival in colon cancer. However, the effect of RAS mutation on recurrence-free survival and recurrence patterns remains unclear. This exploratory study aimed to evaluate the impact of RAS mutations, especially the rare mutations type in recurrence patterns in patients with stage I-IV CRC, and to identify the risk factors predicting recurrence-free survival in colon cancer.
Methods
Full RAS mutations were analyzed using Sanger and pyrosequencing for 270 patients. The MSI status was determined using immunohistochemical analysis. The correlation between Molecular alterations and recurrence patterns and recurrence-free survival was investigated. Statistical analysis was performed using the Kaplan–Meier method and the log-rank test.
Results
The mean patient's age was 55,4±14.7 with a moderate dominance of the male sex (n=146; 54.1%). The rate of recurrence after the first-line therapy was 31.5% (n=85). 13 (15,3%) patients had local recurrence, and 72 (84,7%) had distal recurrence. The most common distal recurrence site was the liver (n=34 ; 40,0%), followed by the lung (n=19 ; 22,4%). Of the 270 patients, 85 (31,5%) experienced recurrence, among whom 52,9% had mutant full RAS status, and 48,2% had KRAS mutations. Outside KRAS exon 2 mutations or rare mutations, were identified in 22 (8.1%) patients. The p.Q61L (Nras exon 3) mutation had the highest frequency in the rare mutation group (n=5 ; 22,7%), followed by the p.A146T (Kras exon 4) variant (n=4 ; 18,2%). RAS mutation status, KRAS mutations, and rare mutations were more common in patients with lung recurrence. Rare mutation status was correlated with worse recurrence-free survival (p=0,001). Multivariate logistic regression analysis revealed that differentiation, perineural invasion, full RAS mutant status, and KRAS codon 12 mutations were independent factors for recurrence-free survival in colon cancer.
Conclusions
In this cohort, recurrence patterns seemed to be associated with rare RAS mutations. KRAS codon 12 mutations were the worst predictor of recurrence-free survival at all stages in our population.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
20P - Effects of <italic>Apis dorsata</italic> honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cells
Presenter: Jose Kenneth Narag
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Hsa_circ_0009061 inhibits the progression of bladder cancer through the miR-889-3p/CPEB3 axis
Presenter: Minkang Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma
Presenter: Vidushi Durani
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients
Presenter: Samuel Doré
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - High-throughput plasma proteomics profiling in early breast cancer
Presenter: Isabella Lombardo
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Immunohistochemical analysis of ROR1 and BMI-1 expression in luminal breast cancer
Presenter: Sergey Vtorushin
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Associations between cancer stem cells (CSC) markers and androgen (AR) and estrogen (ER) receptors expression in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Proteomic profiling reveals organ-specific differences in metastases and identifies potential biomarkers for recurrence risk in localized colon cancer
Presenter: Blanca García-Micó
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT)
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma
Presenter: Rashmi Rana
Session: Cocktail & Poster Display session
Resources:
Abstract